UK BIA To Push For Post-Brexit Regulatory Agreement With EU
Effective Preparation Seems To Have Averted Supply Disruptions So Far
Executive Summary
There may not be a great deal in the new UK-EU trade and cooperation deal for the life sciences industry but a new working group could act as the forum for constructive discussions on regulatory cooperation.
You may also be interested in...
UK/Canada Deal Lets Drug Agencies Avoid Brexit-Related Trade Disruption
An interim trade deal between the UK and Canada means that the regulators in these countries will carry on accepting each other’s batch testing and GMP certificates.
EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.